000342940 001__ 342940
000342940 005__ 20230827173408.0
000342940 0247_ $$2CORDIS$$aG:(EU-Grant)101069368$$d101069368
000342940 0247_ $$2CORDIS$$aG:(EU-Call)ERC-2022-POC1$$dERC-2022-POC1
000342940 0247_ $$2originalID$$acorda_____he::101069368
000342940 035__ $$aG:(EU-Grant)101069368
000342940 150__ $$aMINIMAL SAPONIN-BASED ADJUVANT VACCINE PLATFORM$$y2024-03-01 - 2025-08-31
000342940 372__ $$aERC-2022-POC1$$s2024-03-01$$t2025-08-31
000342940 450__ $$aADJU-PLATFORM$$wd$$y2024-03-01 - 2025-08-31
000342940 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000342940 680__ $$aADJU-PLATFORM seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the efficient production of optimised saponin adjuvants and improved cost-effective vaccines. We have recently developed in the laboratory a potent, safe, stable and streamlined platform based on an optimised version of the vaccine adjuvant QS-21 that has led to patent applications and raised the interest of the pharmaceutical industry. In this PoC project, we aim to exploit our synthetic saponin technology to produce scalable adjuvant and vaccine candidates that outperform existing products more cost-effectively, lowering the risk profile of the commercialisation potential, while also achieving valorisation outcomes for market entry. The goal is to demonstrate our innovative minimal adjuvant platform in relevant settings for the advancement of novel adjuvant prototypes and molecular vaccines closer to the market. 

The breakthrough innovation potential of ADJU-PLATFORM lies in the exploitation of this adjuvant vaccine platform for its application with additional formulation systems in a range of disease areas, expanding and improving the available vaccine solutions. The high purity and excellent chemical control over our synthetic platform compared to the heterogeneous natural product adjuvants, as well as its streamlined, modular nature and low-cost profile are distinctive attributes of our technology that will be valorised herein, making it a potentially superior alternative to existing vaccine models with less structural definition and costlier timelines. The main objectives are (1) demonstrate our synthetic technology platform for the streamlined and efficient development of scalable adjuvant and vaccine solutions and (2) implement valorisation opportunities of our platform and products by establishing an optimal IPR strategy and a “go-to-market” roadmap for the commercialisation.
000342940 909CO $$ooai:juser.fz-juelich.de:1012300$$pauthority:GRANT$$pauthority
000342940 909CO $$ooai:juser.fz-juelich.de:1012300
000342940 980__ $$aG
000342940 980__ $$aCORDIS
000342940 980__ $$aAUTHORITY